scholarly journals Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study

2019 ◽  
Vol 9 (2) ◽  
pp. 351-368 ◽  
Author(s):  
Peng Wei ◽  
Bo Liu ◽  
Ruifeng Wang ◽  
Yinglei Gao ◽  
Lanlan Li ◽  
...  
Keyword(s):  
Structural Characterization ◽  
Structure Activity Relationship ◽  
In Vivo Study ◽  
Activity Relationship ◽  
Structure Activity ◽  
Scaffold Structure ◽  
Crystal Structural

Antiasthmatic acetophenones — an in vivo study on structure activity relationship

Phytomedicine ◽  
1994 ◽  
Vol 1 (1) ◽  
pp. 47-54 ◽  
Author(s):  
W. Dorsch ◽  
A. Müller ◽  
V. Christoffel ◽  
H. Stuppner ◽  
S. Antus ◽  
...  
Keyword(s):  
Structure Activity Relationship ◽  
In Vivo Study ◽  
Activity Relationship ◽  
Structure Activity

scholarly journals Synthesis, Anticancer Activity, and Preliminary Pharmacokinetic Evaluation of 4,4-Disubstituted Curcuminoid 2,2-bis(Hydroxymethyl)Propionate Derivatives

Molecules ◽  
2020 ◽  
Vol 25 (3) ◽  
pp. 479 ◽  
Author(s):  
Der-Yen Lee ◽  
Yu-Chi Hou ◽  
Jai-Sing Yang ◽  
Hui-Yi Lin ◽  
Tsu-Yuan Chang ◽  
...  
Keyword(s):  
Anticancer Activity ◽  
Functional Groups ◽  
Hydrolysis Product ◽  
Structure Activity Relationship ◽  
Ester Hydrolysis ◽  
Activity Relationship ◽  
Structure Activity ◽  
Hct 116 ◽  
Pharmacokinetic Evaluation

Compound 1 is a curcumin di-O-2,2-bis(hydroxymethyl)propionate that shows significant in vitro and in vivo inhibitory activity against MDA-MB-231 cells with eight to ten-fold higher potency than curcumin. Here, we modified the α-position (C-4 position) of the central 1,3-diketone moiety of 1 with polar or nonpolar functional groups to afford a series of 4,4-disubstituted curcuminoid 2,2-bis(hydroxymethyl)propionate derivatives and evaluated their anticancer activities. A clear structure–activity relationship of compound 1 derivatives focusing on the functional groups at the C-4 position was established based on their anti-proliferative effects against the MDA-MB-231 and HCT-116 cell lines. Compounds 2–6 are 4,4-dimethylated, 4,4-diethylated, 4,4-dibenzylated, 4,4-dipropargylated and 4,4-diallylated compound 1, respectively. Compounds 2m–6m, the ester hydrolysis products of compounds 2–6, respectively, were synthesized and assessed for anticancer activity. Among all compound 1 derivatives, compound 2 emerged as a potential chemotherapeutic agent for colon cancer due to the promising in vivo anti-proliferative activities of 2 (IC50 = 3.10 ± 0.29 μM) and its ester hydrolysis product 2m (IC50 = 2.17 ± 0.16 μM) against HCT-116. The preliminary pharmacokinetic evaluation of 2 implied that 2 and 2m are main contributors to the in vivo efficacy. Compound 2 was further evaluated in an animal study using HCT-116 colon tumor xenograft bearing nude mice. The results revealed a dose-dependent efficacy that led to tumor volume reductions of 27%, 45%, and 60% at 50, 100, and 150 mg/kg doses, respectively. The established structure–activity relationship and pharmacokinetic outcomes of 2 is the guidance for future development of 4,4-disubstituted curcuminoid 2,2-bis(hydroxymethyl)- propionate derivatives as anticancer drug candidates.

Sign in / Sign up

Export Citation Format

Share Document